Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
My Bing
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Trending on Bing
Willing to run for president
Innocent after 43-yrs of jail
'I learned nothing'
US killed top ISIS leader?
2024 US Open
WWII plane crash: 2 killed
Honeybees detect cancer?
Voyager 1 is back online
2nd American goes missing
Calif. County wildfire
Returns key to NYC
'Lucky to be here'
On predicting Dec rate cut
WWII plane remains found
Juneteenth event shooting
Honduras plans 'megaprison'
Challenges Biden to a test
Heading to 4th Olympics
Hajj pilgrims die from heat
Oilers rout Panthers
Royals beat Dodgers 7-2
Poll: Black voters' support
Alwyn breaks silence on split
Victim of 1983 murder ID'd
‘Politics in everything’
Mark 27 years of marriage
Lawmakers pass AZ budget
Breaks attendance record
Heat wave on Father’s Day
Warns on terrorist threat
IDF to begin 'tactical pause'
Biden slams Supreme Court
Speaks w/ voters in Detroit
Khanna won't attend address
Halts AI model launch in EU
Murder suspect arrested
On 2020 election results
‘Confident' of UFC return
RU kills 6 hostage takers
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
New: The FDA has expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
FDA approves RSV vaccine for adults 50 to 59
The Arexvy respiratory syncytial virus (RSV) vaccine, which is already approved for adults 60 and up, is now indicated for use in people ages 50 to 59 years old thanks to recent Food and Drug Administration approval.
FDA Expands Use of RSV Vaccine to Include More Adults
The FDA expanded the approval of GSK's respiratory syncytial virus (RSV) vaccine (Arexvy) to include adults ages 50 to 59 at risk of RSV-related lower respiratory tract disease (LRTD) due to underlying conditions, the company announced on Friday.
US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label
The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
FDA Gives Nod to RSV Vaccine for People in Their 50s
For the first time, an RSV vaccine has been approved for use in adults in their fifties. GSK's Arexy appears to have similar safety for folks ages 50-59 as that see
Adults 60+ Will Have 3 RSV Vaccines to Choose From This Year
Moderna's RSV vaccine, the first RSV vaccine to use mRNA, earned FDA approval for adults 60 and up. Here's what you need to know.
FDA approves Moderna's RSV vaccine, its second marketed product
The Food and Drug Administration approved Moderna's RSV vaccine to prevent lower respiratory tract disease in adults aged 60 or older
FDA Approves New RSV Vaccine for Individuals Aged 50-59
On Friday, the Food and Drug Administration (FDA) approved Arexvy, a vaccine designed to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), for
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
GSK GSK announced that the FDA has approved the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy for adults aged 50-59 who are at increased risk of RSV disease. Arexvy is currently approved in the United States,
Des Moines Register
16d
FDA approves Moderna's RSV vaccine, its second marketed product
The U.S. Food and
Drug
Administration has approved Moderna's
respiratory syncytial virus
vaccine
, the company announced on Friday, giving it a shot at much-needed new revenue from a second ...
The American Journal of Managed Care
5d
FDA Approves Expanded Age Indication for RSV Vaccine Arexvy
The first
respiratory syncytial virus
(
RSV
)
vaccine
has been approved for adults aged 50 to 59 years who are at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback